Repligen (NASDAQ:RGEN) Price Target Raised to $175.00

Repligen (NASDAQ:RGEN) had its price objective hoisted by stock analysts at JPMorgan Chase & Co. from $165.00 to $175.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 23.07% from the company’s previous close.

Several other brokerages also recently issued reports on RGEN. Canaccord Genuity Group reduced their price target on shares of Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Roth Capital started coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. HSBC reduced their target price on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Jefferies Financial Group reissued a “hold” rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $166.07.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $3.15 during midday trading on Wednesday, hitting $142.19. 839,526 shares of the stock were exchanged, compared to its average volume of 1,017,253. The stock has a market cap of $8.02 billion, a P/E ratio of 157.81, a PEG ratio of 2.53 and a beta of 1.06. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a 50 day moving average price of $132.95 and a 200-day moving average price of $131.88.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the firm earned $0.26 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts forecast that Repligen will post 1.99 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.60% of the company’s stock.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in RGEN. United Capital Financial Advisors LLC acquired a new position in shares of Repligen during the third quarter worth about $368,387,000. Opti Capital Management LP purchased a new stake in shares of Repligen during the 4th quarter valued at about $2,399,209,000. Maverick Capital Ltd. purchased a new stake in shares of Repligen during the 1st quarter valued at about $178,946,000. Wasatch Advisors LP acquired a new position in Repligen during the 1st quarter worth approximately $146,513,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in Repligen during the 4th quarter worth approximately $199,176,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen News Summary

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen’s second-quarter revenue rose 12% year over year to $204.1 million, exceeding the roughly $201.6 million consensus estimate. Adjusted EPS of $0.54 also beat expectations of $0.45, while adjusted operating income increased 55% to $34 million. Repligen earnings report
• Positive Sentiment: Management raised its 2026 organic revenue-growth outlook to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, above the approximately $2.00 analyst consensus. Total revenue is expected to reach $813 million-$835 million. Repligen Q2 2026 results and guidance
• Positive Sentiment: Repligen cited continued order momentum and stronger visibility into the second half. Its planned acquisition of BioLife Solutions is expected by management to accelerate cell-therapy exposure and be accretive to revenue growth, margins and adjusted EPS. Repligen Q2 beat and higher outlook
• Neutral Sentiment: Analyst views remain mixed: William Blair maintained a Buy rating, while Canaccord Genuity reiterated Hold with an unchanged $145 price target, arguing that operational momentum is offset by a full valuation. The six-month median target cited by QuiverQuant is $160. Repligen analyst rating
• Negative Sentiment: GAAP net income fell to $5.0 million from $14.9 million, and GAAP diluted EPS declined to $0.09 from $0.26. The GAAP net margin also narrowed to 2.5%, partly reflecting acquisition-related, restructuring and other charges. Repligen Q2 revenue report
• Negative Sentiment: At a reported price-to-earnings ratio above 150, investors may be taking profits after the earnings rally. Recent open-market insider activity also consisted of sales by the CEO and CFO, adding a modest sentiment headwind.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.